All Stories

  1. The pharmacology underlying the unique antipsychotic efficacy of clozapine
  2. Air pollution and psychiatric outcomes - is Mendelian randomisation an appropriate analysis?
  3. Xanomeline/Trospium Combination
  4. Proteomic associations with cognitive variability as measured by the Wisconsin Card Sorting Test in a healthy Thai population: A machine learning approach
  5. Understanding the Therapeutic Action of Antipsychotics: Not yet Beyond Striatal Dopamine? A Comment on Direktor et al. (2024)
  6. The trace amine-associated receptor 1 agonists – non-dopaminergic antipsychotics or covert modulators of D2 receptors?
  7. Comment on Tabatabaei Dakhili et al. The Antipsychotic Dopamine 2 Receptor Antagonist Diphenylbutylpiperidines Improve Glycemia in Experimental Obesity by Inhibiting Succinyl-CoA:3-Ketoacid CoA Transferase. Diabetes 2023;72:126–134
  8. Dopamine partial agonists: a discrete class of antipsychotics
  9. Subchronic PCP effects on DNA methylation and protein expression of NMDA receptor subunit genes in the prefrontal cortex and hippocampus of female rats
  10. The neurochemical pathology of schizophrenia: post-mortem studies from dopamine to parvalbumin
  11. High dose antipsychotic polypharmacy and dopamine partial agonists - time to rethink guidelines?
  12. The Etiology of Metabolic Disturbances in Schizophrenia: Drugs, Genes, and Environment
  13. Changes of BDNF exon IV DNA methylation are associated with methamphetamine dependence
  14. Early life trauma, DNA methylation and mental illness
  15. The relationship of childhood trauma and DNA methylation of NMDA receptor genes in first-episode schizophrenia
  16. Schizophrenia, Depressive Symptoms, and Antipsychotic Drug Treatment
  17. Epigenetic-Mediated N -Methyl-D-Aspartate Receptor Changes in the Brain of Isolated Reared Rats
  18. Circulating microRNA changes in patients with impaired glucose regulation
  19. Agricultural work and reduced circulating uric acid are both associated with initial hospital admission for Parkinson’s disease
  20. Neuromyelitis optica spectrum disorder in three generations of a Chinese family
  21. Adjunctive Lurasidone Suppresses Food Intake and Weight Gain Associated with Olanzapine Administration in Rats
  22. GRIN2B promoter methylation deficits in early-onset schizophrenia and its association with cognitive function
  23. Lower uric acid is associated with poor short-term outcome and a higher frequency of posterior arterial involvement in ischemic stroke
  24. Increased DNA methylation in the parvalbumin gene promoter is associated with methamphetamine dependence
  25. Association of polymorphisms in GAD1 and GAD2 genes with methamphetamine dependence
  26. DAT1 methylation is associated with methylphenidate response on oppositional and hyperactive-impulsive symptoms in children and adolescents with ADHD
  27. Modelling the cognitive and neuropathological features of schizophrenia with phencyclidine
  28. Subchronic administration of phencyclidine produces hypermethylation in the parvalbumin gene promoter in rat brain
  29. Blood oxygen level-dependent signals via fMRI in the mood-regulating circuit using two animal models of depression are reversed by chronic escitalopram treatment
  30. TPH-2 Polymorphisms Interact with Early Life Stress to Influence Response to Treatment with Antidepressant Drugs
  31. Effect of Methamphetamine Exposure on Expression of Calcium Binding Proteins in Rat Frontal Cortex and Hippocampus
  32. BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment
  33. Does DNA methylation influence the effects of psychiatric drugs?
  34. Does elevated peripheral benzodiazepine receptor gene expression relate to cognitive deficits in methamphetamine dependence?
  35. Concurrent Risperidone Administration Attenuates the Development of Locomotor Sensitization Following Sub-Chronic Phencyclidine in Rats
  36. Association of brain-derived neurotrophic factor valine to methionine polymorphism with sexual dysfunction following selective serotonin reuptake inhibitor treatment in female patients with major depressive disorder
  37. BDNF (Val66Met) genetic polymorphism is associated with vulnerability for methamphetamine dependence
  38. Genetic association of LMAN2L gene in schizophrenia and bipolar disorder and its interaction with ANK3 gene polymorphism
  39. Polymorphisms of serotonin neurotransmission and their effects on antipsychotic drug action
  40. Analysis of sociability and preference for social novelty in the acute and subchronic phencyclidine rat
  41. Numerical Methods on Population Balances
  42. Pharmacogenomics in psychiatry: the relevance of receptor and transporter polymorphisms
  43. Association of FTO, LEPR and MTHFR gene polymorphisms with metabolic syndrome in schizophrenia patients receiving antipsychotics
  44. Methylation at a transcription factor-binding site on the 5-HT1A receptor gene correlates with negative symptom treatment response in first episode schizophrenia
  45. Association of ADRA2A and MTHFR gene polymorphisms with weight loss following antipsychotic switching to aripiprazole or ziprasidone
  46. SMARTS (Systematic Monitoring of Adverse events Related to TreatmentS): The development of a pragmatic patient-completed checklist to assess antipsychotic drug side effects
  47. Methylenetetrahydrofolate reductase (MTHFR) 677C/T polymorphism is associated with antipsychotic-induced weight gain in first-episode schizophrenia
  48. Genetic variation of GRIN1 confers vulnerability to methamphetamine-dependent psychosis in a Thai population
  49. Lithium in patients with amyotrophic lateral sclerosis (LiCALS): a phase 3 multicentre, randomised, double-blind, placebo-controlled trial
  50. Association of a functional FAAH polymorphism with methamphetamine-induced symptoms and dependence in a Malaysian population
  51. Influence of genetic polymorphisms in the glutamatergic and GABAergic systems and their interactions with environmental stressors on antidepressant response
  52. The obesity risk gene FTO influences body mass in chronic schizophrenia but not initial antipsychotic drug-induced weight gain in first-episode patients
  53. Histamine and antipsychotic drug-induced weight gain
  54. Peripheral PDLIM5 expression in bipolar disorder and the effect of olanzapine administration
  55. Pharmacogenetic Aspects of Antipsychotic Drug-induced Weight Gain - A Critical Review
  56. An association between genotypic variations and protein expression of the glial glutamate transporter 2 in the human nucleus accumbens
  57. The Effect of Chronic Antipsychotic Drug on Hypothalamic Expression of Neural Nitric Oxide Synthase and Dopamine D2 Receptor in the Male Rat
  58. Special issue on Pharmacogenetics
  59. The Pharmacogenetics of Symptom Response to Antipsychotic Drugs
  60. The Pharmacogenetics of Antipsychotic Treatment
  61. Learning and Memory Alterations Are Associated with Hippocampal N-acetylaspartate in a Rat Model of Depression as Measured by 1H-MRS
  62. Receptor mechanisms of antipsychotic drug action in bipolar disorder – focus on asenapine
  63. The Dose‐Dependent Effect of Chronic Administration of Haloperidol, Risperidone, and Quetiapine on Sexual Behavior in the Male Rat
  64. Influence and interaction of genetic polymorphisms in the serotonin system and life stress on antidepressant drug response
  65. Sexual dysfunction in male schizophrenia: influence of antipsychotic drugs, prolactin and polymorphisms of the dopamine D2 receptor genes
  66. Functional consequences of twoHTR2Cpolymorphisms associated with antipsychotic-induced weight gain
  67. Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology
  68. Hippocampal neurochemistry is involved in the behavioural effects of neonatal maternal separation and their reversal by post-weaning environmental enrichment: A magnetic resonance study
  69. Differential regional N-acetylaspartate deficits in postmortem brain in schizophrenia, bipolar disorder and major depressive disorder
  70. Adolescent escitalopram administration modifies neurochemical alterations in the hippocampus of maternally separated rats
  71. The physical health challenges in patients with severe mental illness: cardiovascular and metabolic risks
  72. Clorgyline-mediated reversal of neurological deficits in a Complexin 2 knockout mouse
  73. Early response to selective serotonin reuptake inhibitors in panic disorder is associated with a functional 5-HT1A receptor gene polymorphism
  74. The effect of chronic antipsychotic drug administration on nitric oxide synthase activity and gene expression in rat penile tissues
  75. Tryptophan depletion impairs object-recognition memory in the rat: Reversal by risperidone
  76. Effect of pretreatment with risperidone on phencyclidine-induced disruptions in object recognition memory and prefrontal cortex parvalbumin immunoreactivity in the rat
  77. Effect of subchronic phencyclidine administration on sucrose preference and hippocampal parvalbumin immunoreactivity in the rat
  78. Metabolic side effects of antipsychotic drug treatment – pharmacological mechanisms
  79. Schizophrenia-related endophenotypes in heterozygous neuregulin-1 ‘knockout’ mice
  80. Functional Pharmacogenetics of Serotonin Receptors in Psychiatric Drug Action
  81. Neonatal lipopolysaccharide induces pathological changes in parvalbumin immunoreactivity in the hippocampus of the rat
  82. Olanzapine-induced weight gain in the rat: role of 5-HT2C and histamine H1 receptors
  83. Single drop behaviour in a high shear granulator
  84. Disturbances in social interaction occur along with pathophysiological deficits following sub-chronic phencyclidine administration in the rat
  85. The neurochemistry of schizophrenia
  86. Effect of acute tryptophan depletion on noradrenaline and dopamine in the rat brain
  87. PHARMACOGENETICS OF THE METABOLIC CONSEQUENCES OF ANTIPSYCHOTIC DRUGS
  88. PHARMACOGENETICS OF NEGATIVE SYMPTOM RESPONSE TO ANTIPSYCHOTIC DRUGS - THE ROLE OF 5-HT SYSTEMS
  89. Influence of 5-HT2C receptor and leptin gene polymorphisms, smoking and drug treatment on metabolic disturbances in patients with schizophrenia
  90. Erratum
  91. Acute tryptophan depletion does not alter central or plasma brain-derived neurotrophic factor in the rat
  92. Ziprasidone and aripiprazole attenuate olanzapine-induced hyperphagia in rats
  93. The impact of pharmacogenetics on the development and use of antipsychotic drugs
  94. Sub-chronic phencyclidine administration increases brain-derived neurotrophic factor in the RAT hippocampus
  95. 5-HT2C receptor gene polymorphisms associated with antipsychotic drug action alter promoter activity
  96. The neuronal pathology of schizophrenia: molecules and mechanisms: Table 1
  97. Sub-chronic psychotomimetic phencyclidine induces deficits in reversal learning and alterations in parvalbumin-immunoreactive expression in the rat
  98. Deficits in parvalbumin and calbindin immunoreactive cells in the hippocampus of isolation reared rats
  99. Acute and chronic tryptophan depletion differentially regulate central 5-HT1A and 5-HT2A receptor binding in the rat
  100. Subcellular Pathology of Human Neurodegenerative Disorders: Alzheimer-Type Dementia and Huntington's Disease
  101. Effect of 5-HT1A Receptor Gene Polymorphism on Negative and Depressive Symptom Response to Antipsychotic Treatment of Drug-Naive Psychotic Patients
  102. The effect of chronic antipsychotic treatment on sexual behaviour, hormones and organ size in the male rat
  103. Schizophrenia, antipsychotics and metabolic disease
  104. Pharmacogenetics of schizophrenia
  105. The 5-HT2C receptor and antipsychoticinduced weight gain - mechanisms and genetics
  106. The effect of atypical and classical antipsychotics on sub-chronic PCP-induced cognitive deficits in a reversal-learning paradigm
  107. Clozapine, but not haloperidol, increases neuropeptide Y neuronal expression in the rat hypothalamus
  108. Selective increases in the cytokine, TNF , in the prefrontal cortex of PCP-treated rats and human schizophrenic subjects: influence of antipsychotic drugs
  109. Metabolic syndrome and schizophrenia * Author's reply:
  110. Actions of antipsychotic drugs on pancreatic  -cell function: contrasting effects of clozapine and haloperidol
  111. An in vitro model of inflammatory neurodegeneration and its neuroprotection
  112. The neurochemistry of schizophrenia
  113. The role of 5-HT2C receptor polymorphisms in the pharmacogenetics of antipsychotic drug treatment
  114. Increased N-acetylaspartate in rat striatum following long-term administration of haloperidol
  115. Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis
  116. Chronic phencyclidine administration induces schizophrenia-like changes in N-acetylaspartate and N-acetylaspartylglutamate in rat brain
  117. Pharmacogenetics of treatment in first-episode schizophrenia: D3 and 5-HT2C receptor polymorphisms separately associate with positive and negative symptom response
  118. Chronic haloperidol or clozapine treatment does not alter parvalbumin immunoreactivity in the rat frontal cortex or hippocampus
  119. The NR1 subunit of the glutamate/NMDA receptor in the superior temporal cortex in schizophrenia and affective disorders
  120. Ziprasidone suppresses olanzapine-induced increases in ingestive behaviour in the rat
  121. Receptor Mechanisms in the treatment of Schizophrenia
  122. Reduced n-acetylaspartate in the temporal cortex of rats reared in isolation
  123. Calcium binding protein markers of GABA deficits in schizophrenia — post mortem studies and animal models
  124. Region specific changes in forebrain 5-hydroxytryptamine1a and 5-hydroxytryptamine2a receptors in isolation-reared rats: an in vitro autoradiography study
  125. Effects of antipsychotics on fat deposition and changes in leptin and insulin levels: Magnetic resonance imaging study of previously untreated people with schizophrenia
  126. Interaction between polymorphisms of the dopamine D3 receptor and manganese superoxide dismutase genes in susceptibility to tardive dyskinesia
  127. Dopamine depletion of the nucleus accumbens reverses isolation-induced deficits in prepulse inhibition in rats
  128. N-acetylaspartate and N-Acetylaspartylglutamate deficits in superior temporal cortex in schizophrenia and bipolar disorder: a postmortem study
  129. Polymorphism of the Promoter Region of the Serotonin 5-HT 2C Receptor Gene and Clozapine-Induced Weight Gain
  130. The atypical antipsychotic ziprasidone, but not haloperidol, improves phencyclidine-induced cognitive deficits in a reversal learning task in the rat
  131. Increased Concentrations of the Neurotoxin 3-Hydroxykynurenine in the Frontal Cortex of HIV-1-Positive Patients
  132. Are Striatal Dopamine D4 Receptors Increased in Schizophrenia?
  133. Selective deficits in prefrontal cortical GABAergic neurons in schizophrenia defined by the presence of calcium-binding proteins
  134. Weight gain, antipsychotic drug treatment and pharmacogenomics
  135. Neuronal calcium-binding proteins and schizophrenia
  136. The increased activity of plasma manganese superoxide dismutase in tardive dyskinesia is unrelated to the Ala-9Val polymorphism
  137. Association of a polymorphism in the promoter region of the serotonin 5-HT2C receptor gene with tardive dyskinesia in patients with schizophrenia
  138. Association of antipsychotic druginduced weight gain with a 5-HT2C receptor gene polymorphism
  139. A selective decrease in the relative density of parvalbumin-immunoreactive neurons in the hippocampus in schizophrenia
  140. Understanding the neurotransmitter pathology of schizophrenia: selective deficits of subtypes of cortical GABAergic neurons
  141. The role of dopamine in motor symptoms in the R6/2 transgenic mouse model of Huntington's disease
  142. The atypical antipsychotic olanzapine enhances ingestive behaviour in the rat: a preliminary study
  143. Brain Neurotransmitter Deficits in Mice Transgenic for the Huntington’s Disease Mutation
  144. Phospholipid fatty acids and neurotoxicity in human neuroblastoma SH-SY5Y cells
  145. GABAergic neuronal subtypes in the human frontal cortex — development and deficits in schizophrenia
  146. Neurochemical correlates of cortical GABAergic deficits in schizophrenia: selective losses of calcium binding protein immunoreactivity
  147. Increased density of glutamate/N-methyl-d-aspartate receptors in superior temporal cortex in schizophrenia
  148. Antipsychotic drug use in neurodegenerative disease in the elderly: problems and potential from a pharmacological perspective
  149. Plasma homovanillic acid in untreated schizophrenia — relationship with symptomatology and sex
  150. Agonist-stimulated GTPγ[35S] binding to 5-HT1A receptors in human post-mortem brain
  151. Dopamine receptors, antipsychotic action and schizophrenia
  152. Antipsychotic drug affinities at α2-adrenoceptor subtypes in post-mortem human brain
  153. Developments in antipsychotic drugs – an update
  154. Receptor mechanisms of antipsychotic drug atypicality
  155. Receptor mechanisms of antipsychotic drug atypicality
  156. Increased density of glutamate/N-methyl-d-aspartate receptors in putamen from schizophrenic patients
  157. Increased peripheral benzodiazepine binding sites in the brain of patients with Huntington's disease
  158. S.17.03 Antipsychotic drugs and neurotransmitter receptor regulation
  159. Deficits of [3H]d-aspartate binding to glutamate uptake sites in striatal and accumbens tissue in patients with schizophrenia
  160. What is an atypical antipsychotic?
  161. Schizophrenia - advances in drug therapy
  162. Parvalbumin-immunoreactive neurons are reduced in the prefrontal cortex of schizophrenics
  163. 5-HT receptors, genes and antipsychotic mechanisms
  164. An improved model for examining delayed excitotoxic neurodegeneration in isolated chick retina
  165. Neurotransmitter receptors, genes and schizophrenia
  166. Imidazoline binding sites in Huntington's and Parkinson's disease putamen
  167. The Importance of Dopamine D4 Receptors in the Action and Development of Antipsychotic Agents
  168. Characterization of [3H]GR 113808 binding to 5-HT4 receptors in brain tissues from patients with neurodegenerative disorders
  169. Consensus on minimal criteria of clinical and neuropathological diagnosis of schizophrenia and affective disorders for post mortem research
  170. Absence of detectable striatal dopamine D4 receptors in drug-treated schizophrenia
  171. Depleted red cell membrane essential fatty acids in drug-treated schizophrenic patients
  172. 5-Hydroxytryptamine (5-HT)4 receptors in post mortem human brain tissue: distribution, pharmacology and effects of neurodegenerative diseases
  173. An investigation of the activities of 3-hydroxykynureninase and kynurenine aminotransferase in the brain in Huntington's disease
  174. Frontal cortex indoleamine-2,3-dioxygenase activity is increased in HIV-1-associated dementia
  175. New Approaches to the Drug Treatment of Schizophrenia
  176. Neurotransmitter Systems in Schizophrenia
  177. Neocortical neurotransmitter markers in Huntington's disease
  178. Arachidonic Acid: A Common Link in the Biology of Schizophrenia?
  179. Deficit of [3H]L-689,560 binding to the glycine site of the glutamate/NMDA receptor in the brain in Huntington's disease
  180. Glutamate in Huntington's disease
  181. Antipsychotic drug mechanisms and neurotransmitter systems in schizophrenia
  182. Differential regulation of cardiac α- and β-adrenoceptors by the sympathetic nervous system
  183. Glutamate stimulates dopamine release from cortical and limbic rat brain in vitro
  184. D-aspartate binding to the glutamate uptake site in human brain tissue ? effects of leucotomy
  185. Hippocampal benzodiazepine receptors in schizophrenia
  186. Hippocampal tin, aluminum and zinc in Alzheimer's disease
  187. Monoamine neurotransmitters and their metabolites in brain regions in alzheimer's disease: A postmortem study
  188. Neurochemical abnormalities in huntington's disease: Neurotoxic mechanisms and neurotransmitter changes
  189. Clozapine has sub-micromolar affinity for 5-HT1A receptors in human brain tissue
  190. Dopamine receptor abnormalities in the striatum and pallidum in tardive dyskinesia: a post mortem study
  191. Pre-frontal structural and functional deficits associated with individual differences in schizotypal personality
  192. Increased brain concentrations of a neurotoxin, 3-hydroxykynurenine, in Huntington's disease
  193. An evaluation of structural and functional prefrontal deficits in schizophrenia: MRI and neuropsychological measures
  194. Developments in the drug treatment of schizophrenia
  195. Erratum
  196. Erratum
  197. Studies on brain monoamine oxidase: a laboratory investigation in neurochemistry for first-year undergraduates
  198. The ratio of plasma phenylalanine to other large neutral amino acids is not a risk factor for tardive dyskinesia
  199. Neuroanatomical Correlates of Skin Conductance Orienting in Normal Humans: A Magnetic Resonance Imaging Study
  200. Electrochemical detection of human brain transmitter amino acids by high-performance liquid chromatography of stable O-phthalaldehyde-sulphite derivatives
  201. Determination of 3-hydroxykynurenine in human brain and plasma by high-performance liquid chromatography with electrochemical detection
  202. [3H]Ditolylguanidine binding to human brain σ sites is diminished after haloperidol treatment
  203. No deficit of pallidal D2 dopamine receptors in Huntington's disease
  204. Structural and Functional Characteristics of the Corpus Callosum in Schizophrenics, Psychiatric Controls, and Normal Controls
  205. Pallidal GABA and chorea in Huntington's disease
  206. [3H]Nipecotic Acid Binding to ?-Aminobutyric Acid Uptake Sites in Postmortem Human Brain
  207. Deficit and hemispheric asymmetry of GABA uptake sites in the hippocampus in schizophrenia
  208. Dementia in Huntington's disease is associated with neurochemical deficits in the caudate nucleus, not the cerebral cortex
  209. Serotonin concentrations and turnover in brains of depressed suicides
  210. Tissue banking and EURAGE
  211. INCREASED BRAIN 3-HYDROXYKYNURENINE IN HUNTINGTON'S DISEASE
  212. (3H]MK-801 binding sites in postmortem brain regions of schizophrenic patients
  213. [3H] GBR 12935 binding to the dopamine uptake site in post-mortem brain tissue in schizophrenia
  214. Frontal Cortical and Left Temporal Glutamatergic Dysfunction in Schizophrenia
  215. Biogenic amines and their metabolites in Alzheimer's disease: noradrenaline, 5-hydroxytryptamine and 5-hydroxyindole-3-acetic acid depleted in hippocampus but not in substantia innominata
  216. Neuropeptides in Alzheimer's disease: a postmortem study
  217. Reduced d-[3H]aspartate binding in Down's syndrome brains
  218. Alzheimer-like cortical amino-acid changes in elderly Down's syndrome
  219. 3H-spiperone binding sites in post-mortem brains from schizophrenic patients: Relationship to neuroleptic drug treatment, abnormal movements, and positive symptoms
  220. Transition Metals, Ferritin, Glutathione, and Ascorbic Acid in Parkinsonian Brains
  221. ALUMINIUM AND ALZHEIMER'S DISEASE
  222. Amino acid neurotransmitter deficits in adult Down's syndrome brain tissue
  223. Post-mortem neurochemistry of schizophrenia
  224. GLUTAMATE DEHYDROGENASE ACTIVITY IN AMYOTROPHIC LATERAL SCLEROSIS
  225. Pathologic Heterogeneity of Alzheimer's Disease-Reply
  226. Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain
  227. Depletion of monoamine transmitters by tetrabenazine in brain tissue in Huntington's disease
  228. Brain Quinolinic Acid in Huntington's Disease
  229. Immunocytochemical studies on the basal ganglia and substantia nigra in Parkinson's disease and Huntington's chorea
  230. ASYMMETRICAL LOSS OF GLUTAMATE RECEPTOR SUBTYPE IN LEFT HIPPOCAMPUS IN SCHIZOPHRENIA
  231. Human cytomegalovirus DNA in the temporal cortex of a schizophrenic patient
  232. A correlative study on hippocampal cation shifts and amino acids and clinico-pathological data in Alzheimer's disease
  233. Decreased glutamic acid and increased 5-hydroxytryptamine in Huntington's disease brain
  234. Alzheimer-like neurotransmitter deficits in adult Down's syndrome brain tissue.
  235. Age and Histopathologic Heterogeneity in Alzheimer's Disease
  236. DOPAMINE RECEPTOR ASYMMETRY IN SCHIZOPHRENIA
  237. HPLC analysis of somatostatin related peptides in putamen of Huntington's Disease patients
  238. Maintenance of cortical somatostatin and monoamine levels in the rat does not require intact cholinergic innervation
  239. Decreased brown adipose tissue thermogenic activity following a reduction in brain serotonin by intraventricular p-chlorophenylalanine
  240. A disorder of cortical GABAergic innervation in Alzheimer's disease
  241. Human brain dopamine receptors in children and aging adults
  242. Neuropathology of Huntington's disease
  243. Region-specific loss of glutamate innervation in Alzheimer's disease
  244. LITHIUM PROPHYLAXIS INHIBITS CHOLINE TRANSPORT IN POST-MORTEM BRAIN
  245. Monoclonal antibodies raised against a subsequence of senile plaque core protein react with plaque cores, plaque periphery and cerebrovascular amyloid in Alzheimer's disease
  246. Reduced high-affinity glutamate uptake sites in the brains of patients with Huntington's disease
  247. Regional distribution of a novel peptide (P7 of 1B236) immunoreactivity in the human central nervous system
  248. Striatal dopamine and homovanillic acid in Huntington's Disease
  249. Cytological brush entrapment: a hazard in the stomach postoperatively.
  250. Dopamine D2 receptor density remains constant in treated Parkinson's disease
  251. Brain serotonin receptors in Huntington's disease
  252. Corticotropin-releasing factor-like immunoreactivity in senile dementia of the Alzheimer type. Reduced cortical and striatal concentrations
  253. Corticotropin-Releasing Factor-like Immunoreactivity in Senile Dementia of the Alzheimer Type
  254. ALZHEIMER-LIKE BRAIN MONOAMINE DEFICITS IN ADULTS WITH DOWN'S SYNDROME
  255. Recombinant DNA studies on stored necropsy brain samples from patients with Huntington's chorea.
  256. [3H]SCH 23390 labeled D1 dopamine receptors are unchanged in schizophrenia and Parkinson's disease
  257. Acute administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine affects the adrenal glands as well as the brain in the marmoset
  258. Distribution of phosphate-activated glutaminase, succinic dehydrogenase, pyruvate dehydrogenase and γ-glutamyl transpeptidase in post-mortem brain from Huntington's disease and agonal cases
  259. Identification of gram-negative bacilli using the autobac IDX
  260. Decreased Proline Endopeptidase Activity in the Basal Ganglia in Huntington's Disease
  261. TETRAHYDROBIOPTERIN METABOLISM IN DEPRESSION
  262. Noradrenaline and schizophrenia
  263. Reduced binding of [3H]ketanserin to cortical 5-HT2 receptors in senile dementia of the Alzheimer type
  264. The pharmacology of Parkinson's disease: l-dopa and beyond
  265. Increased concentrations and lateral asymmetry of amygdala dopamine in schizophrenia
  266. Neuropharmacology: Pathophysiology of schizophrenia — causal role for dopamine or noradrenaline?
  267. SEROTONIN RECEPTORS IN SUICIDE VICTIMS
  268. Loss of pigmented dopamine-β-hydroxylase positive cells from locus coeruleus in senile dementia of alzheimer's type
  269. Chronic clozapine treatment of rats down-regulates cortical 5-HT2 receptors
  270. Dopamine and noradrenalin in the cerebrospinal fluid of schizophrenic patients
  271. Neurotensin in the adrenal medulla
  272. Phenylethylamine and phenylacetic acid in CSF of schizophrenics and healthy controls
  273. Parkinson's disease putamen: Normal concentration of synaptic membrane marker antigens
  274. THIORIDAZINE IS NOT SPECIFIC FOR LIMBIC DOPAMINE RECEPTORS
  275. Determination of a wide range of urinary amine metabolites using a simple high-performance liquid chromatographic technique
  276. DOPAMINE RECEPTORS IN POST-MORTEM SCHIZOPHRENIC BRAINS
  277. The effects of lisuride and some other dopaminergic agonists on receptor binding in human brain
  278. DOPAMINE RECEPTORS AND SCHIZOPHRENIA: DRUG EFFECT OR ILLNESS
  279. The Determination and Distribution of2-Phenylethylamine in Sheep Brain
  280. Deficient production of tyramine and octopamine in cases of depression
  281. Phenylethylamine — a role in mental illness?
  282. Amphetamine and 2-phenylethylamine in post-mortem Parkinsonian brain after (-)deprenyl administration
  283. The effect of urinary pH and flow rate on monoamine output
  284. The urinary excretion of 2-phenylethylamine in phenylketonuria
  285. Deprenyl administration in man: A selective monoamine oxidase B inhibitor without the ?cheese effect?
  286. Gas chromatographic detection of N-methyl-2-phenylethylamine: a new component of human urine
  287. A method for the estimation of 2-phenylethylamine in human urine by gas chromatography
  288. Neurochemical Studies in Human Postmortem Brain Tissue
  289. Neurochemistry of Human Postmortem Brain